DistantNews
Support us
🇮🇩 Indonesia /Health & Science

Indonesia Launches First Botulinum Toxin Plant, Targeting 2028 Production

From Tempo · () Indonesian

Translated from Indonesian, summarized and contextualized by DistantNews.

At a glance

News Named sources New plan
  • Indonesia has opened its first manufacturing plant for botulinum toxin (botox), PT Selatox Bio Pharma.
  • The facility aims to reduce import dependence, lower prices, and enhance product safety, with potential to become a global market hub.
  • Production is slated to begin in 2028 after further certification and trials, with a capacity of 6.5 million vials annually.

PT Selatox Bio Pharma has inaugurated Indonesia's first manufacturing facility dedicated to producing botulinum toxin, commonly known as botox. This development marks a significant step towards reducing the nation's complete reliance on imported botulinum toxin.

Until now, botulinum toxin had to be 100 percent imported. With local production, the prices can be more affordable, ensuring better safety, and Indonesia has the potential to become a global market hub.

— Taruna Ikrar, Head of the National Agency of Drug and Food Control (BPOM)Highlighting the benefits of domestic botulinum toxin production.

Taruna Ikrar, head of the National Agency of Drug and Food Control (BPOM), highlighted the strategic importance of local production. "With local production, the prices can be more affordable, ensuring better safety, and Indonesia has the potential to become a global market hub," she stated during the plant's inauguration in Cikarang, West Java. BPOM has approved five type A botulinum toxin products for both neurological and aesthetic uses, all of which were previously imported.

The facility has already obtained its Good Manufacturing Practice (GMP) certificate, issued on July 10, 2026, after a swift 35-working-day process. Selatox is also conducting phase 3 clinical trials in compliance with BPOM regulations. BPOM encourages the company to explore clinical trials for indications such as post-stroke spasticity and other neurological conditions.

To date, there are 5 type A botulinum toxin products approved by BPOM, with indications for both neurological and aesthetic purposes, namely Botox, Letybo, Xeomin, Nabota, and Lanzox. However, all of these products are still imports.

— Taruna Ikrar, Head of the National Agency of Drug and Food Control (BPOM)Detailing the current import status of botulinum toxin products in Indonesia.

Although the plant has been inaugurated, actual production is scheduled to commence in 2028. The facility, built on a 4,740 square meter site, boasts a production capacity of up to 6.5 million vials per year. Selatox aims to contribute to Indonesia's development as a center for aesthetic bio-pharmaceuticals, integrating research, development, manufacturing, and global business operations.

BPOM also encourages PT Selatox to conduct clinical trials related to indications for post-stroke spasticity and other neurological diseases.

— Taruna Ikrar, Head of the National Agency of Drug and Food Control (BPOM)Encouraging further research and development by PT Selatox.
DistantNews Editorial

Originally published by Tempo in Indonesian. Translated, summarized, and contextualized by our editorial team with added local perspective. Read our editorial standards.

More Stories

From Our Blog